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Abstract: Thrombotic microangiopathies are disorders resulting from platelet thromboses forming in the microvasculature with resultant 
schistocyte forms. Hemolytic uremic syndrome (HUS) is a microangiopathic hemolytic anemia often complicated by acute renal failure 
in children. HUS is typically caused by bacterial infection, most commonly enterohemorrhagic Escherichia coli. Neuraminidase-
producing organisms, such as Streptococcus pneumoniae have also been reported as potential etiologies. The pathogenesis in these cases 
involves cleavage of sialic acid residues from the surfaces of erythrocytes, platelets, and glomerular capillary endothelial cells, exposing 
the Thomsen-Friedenreich antigen, a process known as T-activation. We describe a 2-year-old girl who presented with pneumococcal 
pneumonia and sepsis ultimately resulting in a thrombotic microangiopathy with acute renal failure, most consistent with HUS. The 
patient’s direct antiglobulin test was positive. Polyagglutination was observed with human adult serum, but not with umbilical cord 
serum. Her red blood cells (RBCs) were reactive against peanut and soybean lectins, but not Salvia sclarea or Salvia horminum lectins. 
These findings are consistent with T-activation. Clinicians should be cognizant of the possibility of T-activation with resultant HUS in 
patients infected with neuraminidase-producing bacteria. Such patients may be difficult to identify using monoclonal typing antisera, 
as these typically do not have anti-T antibodies. Whether such patients are at risk for transfusion-associated hemolysis is debatable.
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Introduction
Hemolytic uremic syndrome (HUS), a common cause 
of acute renal failure in children, is one of a group 
of disorders referred to as “thrombotic microangiopa-
thies.” HUS-related symptoms include fever, micro-
angiopathic hemolytic anemia, thrombocytopenia and 
renal failure. Prior association of HUS resulting from 
preceding infection with veracytotoxin or shigella-
like toxin-producing bacteria, in particular the enteric 
pathogen Enterohemorrhagic Escherichia coli (EHEC) 
O157:H7 and other E. coli serotypes have been doc-
umented.1–3  EHEC  results  in  hemorrhagic  bloody 
diarrhea. Additionally, infections involving neuramin-
idase-producing  bacteria,  especially  Streptococcus 
pneumoniae, have also been documented as etiolo-
gies of atypical non-diarrheal HUS.5–7
The pathophysiology involves neuraminidase cleav-
age of the N-acetylneuraminic (sialic) acid from glyco-
proteins in the cell membranes of erythrocytes, platelets 
and glomerular endothelial cells with subsequent expo-
sure of the Thomsen-Friedenreich antigen (T antigen).5 
Anti-T IgM antibodies, present in plasma of humans 
greater than six months of age,8 subsequently bind the 
exposed antigen on involved RBCs, platelets, and endo-
thelial cells (see Fig. 1) with resultant hemolysis, RBC 
polyagglutination, thrombocytopenia, and thrombotic 
renal microangiopathy.9–11
case Report
A two year old Caucasian female presented with fever 
and respiratory difficulty including tachypnea, grunting, 
intercostal retractions, and a cough. A right-sided otitis 
media was also noted. Laboratory values are shown in 
Table 1. Initial X-ray results were significant for bilat-
eral lobar pneumonia, which was consistent with the 
physical exam findings.
Her blood counts decreased over the first three 
days of hospitalization, as can be seen in Table 1. Also 
present  were  elevated  fibrin  degradation  products 
and D-dimer. The patient typed as O positive. No 
reactivity was observed with the Anti-A and Anti-B 
typing reagents, which are of monoclonal origin and 
not  human  source  material.  Monoclonal  antisera 
typically do not contain anti-T. Her direct antiglob-
ulin test was 2+ positive, due to erythrocyte-bound 
complement (C3b, C3d) components. The antibody 
screen,  using  both  low-ionic  strength  saline  and 
polyethylene  glycol-potentiated  tests,  was  nega-
tive, as was a short cold panel. The Donath Land-
steiner  test  for  biphasic  cold  hemagglutinins  was 
also negative.
When tested with several samples of human adult 
and cord serum, the patient’s red blood cells revealed 
strong  reactivity  with  adult  sera  only. The  sample 
was sent to a reference laboratory (ImmucorGamma, 
Houston, TX) for confirmation of polyagglutination 
and for classification of the particular polyaggluti-
nable state. The patient’s red cells were found to be 
reactive (4+) with Arachis hypogaea (peanut lectin) 
and Glycine soja (soybean lectin) and non-reactive 
with Salvia sclarea and Salvia horminum lectins (see 
Table 2), most consistent with T-activation. She was 
transfused with washed RBCs and volume-reduced 
platelets.
Blood culture was positive for S. pneumoniae and 
was identified as Serotype 19A by the Texas Depart-
ment of Health. Nasopharyngeal cultures were nega-
tive for adenoviruses, influenza virus types A and B, 
and parainfluenza types 1, 2, and 3. Fecal cultures were 
negative for E. coli O157:H7 and Campylobacter spp. 
as well as other enteric pathogens. She was hyper-
kalemic and hyperbilirubinemic on hospital day #4, 
consistent  with  hemolysis.  Peripheral  blood  smear 
examination  revealed  schistocytes  and  thrombocy-
topenia consistent with microangiopathic hemolytic 
anemia  (Fig.  2)  in  addition  to  neutrophilic  toxic 
granulation as expected in septicemia. This was con-
sidered most likely HUS because of acute renal fail-
ure (as evidenced by increased serum creatinine and 
Figure 1. Left, schistocytes in peripheral blood, indicative of microangio-
pathic hemolytic anemia (Wright-Giemsa, ×600). right, Closer view of 
schistocyte and neutrophilic toxic granulation (Wright-Giemsa, ×1000).Pneumococcal T-activation
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blood  urea  nitrogen)  and  known  association  with 
pneumococcal infections and T-activation, although 
confirmation with ADAMTS13 was not performed. 
The patient ultimately required mechanical ventila-
tion to treat metabolic acidosis prior to transfer to an 
institution capable of pediatric dialysis.
The  patient’s  diagnoses  upon  transfer  included  throm-
botic microangiopathy most likely HUS with acute 
renal failure secondary to pneumococcal pneumonia 
and sepsis, acute respiratory distress syndrome, pneu-
mothoraces, and pleural effusions ultimately requiring 
bilateral thoracostomy tube placement after transfer. 
Upon  transfer,  the  patient  underwent  3  weeks  of 
continuous  ambulatory  peritoneal  dialysis  (CAPD) 
followed by nighttime intermittent peritoneal dialysis 
(NIPD). The patient’s urine output slowly improved. 
A  renal  biopsy  performed  some  time  later  at  the 
outside  institution  revealed  acute  tubular  necrosis 
(ATN) without evidence of cortical necrosis. Fibrosis 
involved  approximately  25%  of  the  interstitium. 
Surprisingly, no microthrombi were seen. Considered 
was the possibility that ATN secondary to sepsis was 
the primary disease process; ATN, however, is not 
typically associated with microangiopathic hemolytic 
anemia or T-activation. The patient was ultimately 
discharged on hospital day #36. At the one week follow-
  up appointment, her physical exam was normal as was 
her blood pressure. Significant laboratory values are 
listed in Table 1.
The patient was instructed to avoid crowded places 
for 2–3 months and to receive the influenza vaccine 
in order to minimize the chances of acquiring any 
respiratory illness. The long-term renal prognosis for 
this patient appears to be good in light of her normal 
physical exam, normal blood pressure, and normal 
renal function, although careful follow-up is ongoing 
because of her prolonged ATN and the presence of 
interstitial fibrosis on biopsy.
Table 1. Pertinent laboratory data.
Test Admission Day #3 Day #4 Day #10 Follow-up Reference range
WBC count 24.7 34.2 14.3 6.5 6–17 k/µL
Hemoglobin 11.6 5.0 7.3 8.8 10.5–13.5 mg/dL
Hematocrit 35.5 14.4 27.0 33%–39%
Platelet count 471 44 85 366 140–400 k/µL
sodium 142 145 137–145 mmol/L
Potassium 6.6 3.9 3.6–5.0 mmol/L
Chloride 116 111 98–107 mmol/L
Bicarbonate 17 24 22–30 mmol/L
Blood urea nitrogen (BUN) 20 71 82 8 9–20 mg/dL
Creatinine 3.5 0.4 0.8–1.5 mg/dL
Glucose 91 92 65–110 mg/dL
AsT 194 17–59 IU/L
ALT 33 21–72 IU/L
Total bilirubin 5.1 2.3 0.2–1.3 mg/dL
PT 13.8 10.4–13.1 sec
PTT       41.1   24.3–32.8 sec
Table 2. Differentiation of  polyagglutinable states. Charac-
teristic agglutination patterns to various lectins.
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Discussion
This case is not meant to provide new information on 
the topic of T-activation, but is meant to be a review 
of a relatively uncommon clinical phenomenon.
Polyagglutination
Polyagglutinable  RBCs  are  red  blood  cells  agglu-
tinated by a large proportion of human adult serum, 
regardless of blood group, and are usually non-reactive 
with  their  autologous  serum  or  serum  from  cord 
blood samples.12 Principle causes of polyagglutina-
tion are modification of RBC membrane structure by 
microbial enzymes, incomplete biosynthesis of RBC 
membrane-associated carbohydrates, and inheritance 
of uncommon haplotypes. Several forms of polyagglu-
tination have been described. Those associated with 
microbial infection are T, Tk, Th, Tx, and acquired B. 
Tn syndrome is a typical cause of polyagglutination 
by incomplete biosynthesis, while those due to inheri-
tance are Cad, NOR, HEMPAS, VA, and Hemoglobin 
M-Hyde Park.13,14 Differentiation can be made by use 
of seed extracts, known as lectins (except for NOR). 
Reaction  patterns  of  some  of  the  polyagglutinable 
states with a lectin panel are depicted in Table 2.12,13
T-activation
Primary populations affected by T-activation include 
children  with  necrotizing  enterocolitis,  EHEC,  and 
serious  Streptococcus  pneumoniae  infections.  Adult 
T-activation has been demonstrated in patients with 
sepsis, gastrointestinal disorders, as well as respira-
tory and wound infections. T antigen sites have been 
demonstrated  on  red  cells,  platelets,  white  blood 
cells, and tissue cells. In HUS patients specifically, 
the T-antigen has been demonstrated to be present 
on  the  glomerular  capillary  loops  and  renal  tubu-
lar epithelium.14,15 T antigens, normally hidden, are 
exposed when neuraminidases are released from bac-
terial organisms which then cleave the sialic acid resi-
dues covering the T-antigens (Fig. 2).8,13,16 T-activation 
can be identified by the red cells’ reactions with the 
lectins derived from peanuts, Arachis hypogaea and 
their reactions with soybean lectin, Glycine soja.13,17,18 
(Table 2). T-activation caused by bacterial infections 
may occur quickly in vivo, but is usually transient, 
resolving within weeks or months. Additionally, pre-
vious research has revealed approximately 0.5% of 
healthy  individuals  may  also  be  affected  with  this 
condition.16
Anti-T, a naturally occurring antibody, reacts best at 
room temperature or colder, rather than at 37 °C, and 
does not appear to activate complement. The antibody 
is predominately IgM, which likely forms as a result 
of  exposure  to  intestinal  flora  with  bacterial  struc-
tures that have antigenic similarity to red blood cell 
cryptantigens. T antibodies, found in all human adult 
sera, begin to develop between 3 and 6 months of age 
and are present at adult levels by two years of age.16
Transfusion of patients 
with T-polyagglutination
The concern of transfusing patients with T-activated 
RBCs is related to the possibility of anti-T antibodies 
present in plasma-containing blood products causing 
hemolysis.  Hemolysis  in  patients  with  T-activation 
has been reported, whether or not the patient has been 
transfused.  Some  reports  show  that  no  hemolysis 
was observed after transfusion of anti-T containing 
products,15  while  very  severe  hemolysis  and  death 
have been reported in other patients.8 Post-transfusion 
hemolysis may be related or dependent on the cause 
of  T-activation. In addition to hemolysis, patients with 
S. pneumoniae associated-HUS with T-activation may 
be subject to renal damage from transfusion of anti-T 
containing blood products. However, transfusion may 
be required for the hemostatic factors provided in these 
components and may outweigh the risk of hemolysis 
associated with passive transfusion of anti-T.16
Therefore, the prudent course of action would be 












Figure 2. The pathogenesis of hemolytic uremic syndrome in S. pneumoniae 
induced T-activation involves cleaving of sialic acid residues from erythrocyte 
and renal tubular cell membranes by bacterial neuraminidase, resulting in 
exposure of the underlying T antigen, which becomes bound by anti-T IgM. 
(Adapted from Journal of Pediatric Surgery, Vol. 16, seges, Kenny, Bird, 
et al. Pediatric surgical patients with severe anaerobic infection: report of 16 
T-antigen positive cases and possible hazards of blood transfusion, 905-10, 
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of  anti-T  antibody.  Blood  products  and  derivatives 
containing small amounts of IgM include cryoprecipitate, 
purified albumin concentrates, and IVIG. If RBC trans-
fusion  is  indicated,  washed  RBCs  or  red  cells  sus-
pended in 10% albumin or plasma protein fraction may 
decrease  hemolytic  complications.  For  selection  of 
donor plasma, a minor crossmatch may be beneficial 
in identifying those units with the lowest anti-T titers.16 
However, other authors have demonstrated that there is 
minimal to no risk of transfusion-associated hemoly-
sis in patients with T-activation,19,20 making this a very 
controversial issue.
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